Editorial update — September 28, 2026. Revised by Averin Capital to remove dated market forecasts and clarify the clinical and operating requirements of care at home. The original publication date and author attribution are retained.
Care at home offers a compelling company-building opportunity when it solves a specific problem for patients and the people responsible for their care. The starting point is not moving every service out of a facility. It is deciding which patients, conditions, and interventions can be served well at home—and building the clinical and operating model around them.
Start with the care pathway
A strong model defines who is eligible, who is accountable for clinical decisions, how patients receive help, and when care must escalate. Patient preference matters, but so do the home environment, caregiver support, connectivity, and the availability of in-person services.
Remote monitoring is useful when the information leads to an appropriate action. More measurements alone do not establish better care. Teams need clear responsibilities for reviewing signals, responding to deterioration, and coordinating with the patient’s existing clinicians.
Technology should make delivery workable
We see opportunities in tools that help clinicians coordinate visits, manage equipment, prioritize follow-up, and share information across settings. AI can support these workflows where it is reliable and where its output can be checked. A product’s value depends on how it fits into daily care, including the exceptions and handoffs that make healthcare difficult.
The relevant evidence is specific to the service and population: patient outcomes, safety, experience, clinician workload, and the resources required to deliver care. A result from one program should not be assumed to apply to every home-care model.
Build the economics from the ground up
Home-based delivery is not automatically less expensive. Staffing, travel, equipment, support coverage, and reimbursement all affect the economics. Founders need to understand who pays, what is reimbursed, how utilization changes, and whether the model remains viable as it expands.
At Averin Capital, we look for companies that combine a clear clinical purpose with a practical delivery model. Durable value comes from making appropriate care easier to access and reliably deliver, with evidence that supports the claim. Market size and hypothetical exit paths cannot substitute for that work.
